Clinical data presented at major oncology conferences, peer-reviewed publications, and company milestones.
ImmunoMet presented its updated clinical data and partnering thesis for lixumistat at BIO International 2026, San Diego Convention Center. Download the full presentation below.
Updated Phase 1b/2a PDAC data presented at the ESMO Gastrointestinal Cancers Symposium.
Phase 1b/2a interim data for lixumistat in advanced pancreatic cancer presented at the ASCO Gastrointestinal Cancers Symposium.
Published results of the completed Phase 1 study (NCT03272256) in patients with advanced solid tumours. Safety profile established; no dose-limiting toxicities.
Interim data from the Phase 1b/2a PDAC trial at MD Anderson. Publication in progress.
Further references to be added.
Reach out for the latest clinical data, the investor deck, or media enquiries.
